Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 3
1985 5
1986 6
1987 30
1988 14
1989 13
1990 36
1991 20
1992 60
1993 40
1994 26
1995 22
1996 55
1997 67
1998 87
1999 92
2000 127
2001 167
2002 148
2003 157
2004 184
2005 175
2006 177
2007 188
2008 161
2009 142
2010 161
2011 139
2012 170
2013 192
2014 153
2015 178
2016 178
2017 161
2018 176
2019 175
2020 154
2021 166
2022 163
2023 179
2024 78

Text availability

Article attribute

Article type

Publication date

Search Results

4,232 results

Results by year

Filters applied: . Clear all
Page 1
How Carvedilol activates beta(2)-adrenoceptors.
Benkel T, Zimmermann M, Zeiner J, Bravo S, Merten N, Lim VJY, Matthees ESF, Drube J, Miess-Tanneberg E, Malan D, Szpakowska M, Monteleone S, Grimes J, Koszegi Z, Lanoiselée Y, O'Brien S, Pavlaki N, Dobberstein N, Inoue A, Nikolaev V, Calebiro D, Chevigné A, Sasse P, Schulz S, Hoffmann C, Kolb P, Waldhoer M, Simon K, Gomeza J, Kostenis E. Benkel T, et al. Nat Commun. 2022 Nov 19;13(1):7109. doi: 10.1038/s41467-022-34765-w. Nat Commun. 2022. PMID: 36402762 Free PMC article.
Yet the mechanisms by which carvedilol achieves this superior clinical profile are still unclear. Beyond blockade of beta(1)-adrenoceptors, arrestin-biased signalling via beta(2)-adrenoceptors is a molecular mechanism proposed to explain the survival benefits. Here, we off …
Yet the mechanisms by which carvedilol achieves this superior clinical profile are still unclear. Beyond blockade of beta(1)-adrenoce …
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.
Turco L, Reiberger T, Vitale G, La Mura V. Turco L, et al. Liver Int. 2023 Jun;43(6):1183-1194. doi: 10.1111/liv.15559. Epub 2023 Apr 17. Liver Int. 2023. PMID: 36897563 Review.
In secondary prophylaxis, the combination of EVL with carvedilol may prevent rebleeding and non-bleeding further decompensation better than that with propranolol. ...The target dose of carvedilol to treat PH should be 12.5 mg/day. This review summarizes the evidence …
In secondary prophylaxis, the combination of EVL with carvedilol may prevent rebleeding and non-bleeding further decompensation bette …
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
Villanueva C, Torres F, Sarin SK, Shah HA, Tripathi D, Brujats A, Rodrigues SG, Bhardwaj A, Azam Z, Hayes PC, Jindal A, Abid S, Alvarado E, Bosch J; Carvedilol-IPD-MA-group and the Baveno Cooperation: an EASL Consortium. Villanueva C, et al. J Hepatol. 2022 Oct;77(4):1014-1025. doi: 10.1016/j.jhep.2022.05.021. Epub 2022 May 31. J Hepatol. 2022. PMID: 35661713 Free article.
The risk of death was also lower with carvedilol (SHR 0.417; 95% CI 0.194-0.896; p = 0.025; I(2) = 0.0%, Q-statistic-p = 0.989). CONCLUSIONS: Long-term carvedilol therapy reduced decompensation of cirrhosis and significantly improved survival in compensated patients …
The risk of death was also lower with carvedilol (SHR 0.417; 95% CI 0.194-0.896; p = 0.025; I(2) = 0.0%, Q-statistic-p = 0.989). CONC …
Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis.
Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Balcar L, Hofer B, Pfisterer N, Schwarz M, Scheiner B, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Jachs M, et al. Clin Gastroenterol Hepatol. 2023 Aug;21(9):2318-2326.e7. doi: 10.1016/j.cgh.2022.06.007. Epub 2022 Jul 14. Clin Gastroenterol Hepatol. 2023. PMID: 35842118 Free article.
Limited data exist on the efficacy of carvedilol in secondary prophylaxis of variceal bleeding. METHODS: Patients undergoing paired HVPG measurements for guiding secondary prophylaxis with either carvedilol or propranolol were included in this retrospective analysis …
Limited data exist on the efficacy of carvedilol in secondary prophylaxis of variceal bleeding. METHODS: Patients undergoing paired H …
Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.
Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY. Zacharias AP, et al. Cochrane Database Syst Rev. 2018 Oct 29;10(10):CD011510. doi: 10.1002/14651858.CD011510.pub2. Cochrane Database Syst Rev. 2018. PMID: 30372514 Free PMC article. Review.
OBJECTIVES: To assess the beneficial and harmful effects of carvedilol compared with traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. ...AUTHORS' CONCLUSIONS: We found no clear beneficial or harmful effects of carvedilol
OBJECTIVES: To assess the beneficial and harmful effects of carvedilol compared with traditional, non-selective beta-blockers for adu …
Reply.
Chen WC, Hou MC. Chen WC, et al. Clin Gastroenterol Hepatol. 2019 Dec;17(13):2825. doi: 10.1016/j.cgh.2019.06.014. Clin Gastroenterol Hepatol. 2019. PMID: 31757367 No abstract available.
Carvedilol attenuates liver fibrosis by suppressing autophagy and promoting apoptosis in hepatic stellate cells.
Meng D, Li Z, Wang G, Ling L, Wu Y, Zhang C. Meng D, et al. Biomed Pharmacother. 2018 Dec;108:1617-1627. doi: 10.1016/j.biopha.2018.10.005. Epub 2018 Oct 10. Biomed Pharmacother. 2018. PMID: 30372864 Free article.
Carvedilol has been identified as a promising agent for the treatment of liver fibrosis. ...Moreover, carvedilol treatment led to the accumulation of yellow dots only in GFP-RFP-LC3-LX-2 cells, similar to the results following CQ treatment, indicating that carved
Carvedilol has been identified as a promising agent for the treatment of liver fibrosis. ...Moreover, carvedilol treatment led
How carvedilol does not activate beta(2)-adrenoceptors.
Lefkowitz RJ, Rockman HA, Shim PJ, Liu S, Ahn S, Pani B, Rajagopal S, Shenoy SK, Bouvier M, Benovic JL, Liggett SB, Ruffolo RR, Bristow MR, Packer M. Lefkowitz RJ, et al. Nat Commun. 2023 Nov 30;14(1):7866. doi: 10.1038/s41467-023-42848-5. Nat Commun. 2023. PMID: 38036531 Free PMC article. No abstract available.
Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-beta-Blocking R-Enantiomer Carvedilol.
Seo K, Yamamoto Y, Kirillova A, Kawana M, Yadav S, Huang Y, Wang Q, Lane KV, Pruitt BL, Perez MV, Bernstein D, Wu JC, Wheeler MT, Parikh VN, Ashley EA. Seo K, et al. Circulation. 2023 Nov 21;148(21):1691-1704. doi: 10.1161/CIRCULATIONAHA.123.065017. Epub 2023 Oct 18. Circulation. 2023. PMID: 37850394
In Myh6(R403Q/+) mice, R-carvedilol normalized hyperdynamic contraction, suppressed arrhythmia, and increased cardiac output better than metoprolol, verapamil, and mavacamten. The ability of R-carvedilol to suppress contractile function was well retained in MYH7(R40 …
In Myh6(R403Q/+) mice, R-carvedilol normalized hyperdynamic contraction, suppressed arrhythmia, and increased cardiac output better t …
Editorial comment.
Woo HH. Woo HH. Urology. 2013 Sep;82(3):665; discussion 665-6. doi: 10.1016/j.urology.2013.03.090. Urology. 2013. PMID: 23987162 No abstract available.
4,232 results